Bone Biologics Corporation (BBLG)

NASDAQ: BBLG · IEX Real-Time Price · USD
-0.15 (-5.03%)
At close: Jan 21, 2022 4:00 PM
0.17 (6.01%)
After-hours:Jan 21, 2022 7:51 PM EST

Company Description

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein.

Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration.

The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1.

Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Bone Biologics Corporation
CountryUnited States
IndustryMedical Devices
SectorHealth Care

Contact Details

2 Burlington Woods Drive
Burlington, MA 01803
United States
Phone781 552 4452

Stock Details

Ticker SymbolBBLG
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code1419554

Key Executives

Jeffrey FrelickPresident and Chief Executive Officer
Deina H. WalshChief Financial Officer
Dr. Shun'ichi KurodaCo-Founder and Member of Scientific Advisory Board

Latest SEC Filings

Dec 22, 20218-KCurrent report
Nov 15, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 2, 2021424B5Prospectus [Rule 424(b)(5)]
Nov 1, 2021SC 13D/AGeneral statement of acquisition of beneficial ownership
Oct 21, 20213Initial statement of beneficial ownership of securities
Oct 21, 20213Initial statement of beneficial ownership of securities
Oct 19, 20214Statement of changes in beneficial ownership of securities
Oct 19, 20218-KCurrent report
Oct 15, 2021424B4Prospectus [Rule 424(b)(4)]
Oct 15, 2021424B4Prospectus [Rule 424(b)(4)]
View All SEC Filings